List view / Grid view
30 October 2013 | By Johnson & Johnson
“The EMA Marketing Authorisation Application is an important milestone in the development of ibrutinib...”
30 October 2013 | By Teva Pharmaceutical Industries Ltd
Dr. Jeremy Levin will step down as President and Chief Executive Officer...
30 October 2013 | By Abbott
The MitraClip device provides physicians with a breakthrough treatment option for patients suffering from MR...
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
29 October 2013 | By kdm communications
Tecan’s newly launched AC Extraction Plate is a revolutionary, automation-friendly solution designed to streamline sample preparation...
29 October 2013 | By GlaxoSmithKline
GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability...
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
28 October 2013 | By Bristol-Myers Squibb
“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
28 October 2013 | By Johnson & Johnson
Breakthrough technology in ultrasonic energy designed to improve surgeon confidence in vessel sealing...
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
